Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 6/20 | 1.00 |
| ▸ | RORC | P51449 | 5/20 | 1.00 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.85 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.85 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.84 |
| ▸ | CRYAB | P02511 | 1/20 | 0.80 |
| ▸ | HMGCR | P04035 | 1/20 | 0.80 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.80 |
| ▸ | ITGAV | P06756 | 1/20 | 0.80 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.80 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.80 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.80 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.77 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.75 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholesterol SCHEMBL21707472 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21539517 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL22095727 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21447271 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21340667 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23365796 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21650234 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23761109 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21445079 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL20607477 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240425545-A1 | 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same | JPMORGAN CHASE BANK, N.A. | 2024-12-26 | — | — | US | disclosed |
| WO-2024138203-A1 | 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, FORMULATIONS THEREOF AND METHODS FOR PREPARING, AND MEDICAL USES OF SAME | DURECT CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024136884-A1 | SALTS INCLUDING CRYSTALLINE SALTS OF 25-HYDROXY-CHOLEST-5-EN-3-SULFATE AND METHODS FOR PREPARING SAME | DURECT CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230056273-A1 | CRYSTALLINE AND LIQUID CRYSTALLINE 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIUM AND METHODS FOR PREPARING SAME | JPMORGAN CHASE BANK, N.A. | 2023-02-23 | — | — | US | disclosed |
| CN-115103591-A | Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sodium sulfate and process for preparing same | 度勒科特公司 | 2022-09-23 | — | — | CN | disclosed |
| WO-2021133976-A1 | CRYSTALLINE AND LIQUID CRYSTALLINE 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIUM AND METHODS FOR PREPARING SAME | DURECT CORPORATION (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | OSBP 140/4885RORC 2949/4885OSBP2 82/4885 |
| US-20240425545-A1 | 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same | CYP27A1, CETP, CYP46A1 | OSBP 480/4885RORC 541/4885OSBP2 412/4885 |
| US-20230056273-A1 | CRYSTALLINE AND LIQUID CRYSTALLINE 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIUM AND METHODS FOR PREPARING SAME | CYP27A1, CYP46A1, PCSK9 | OSBP 329/4885RORC 372/4885OSBP2 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.